Cometriq sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Cometriq cabozantinib from Ipsen to treat advanced renal cell carcinoma (RCC) in adults previously treated with VEGF-targeted therapy. The committee said that the additional benefits of Cometriq compared with current care were “highly uncertain” because the meta-analysis evidence presented by the company was “unreliable.” The committee also said the incremental cost-effectiveness ratios (ICERs) compared with any comparator exceeded £30,000 ($37,383) per quality-adjusted life year (QALY) gained, and it could therefore not recommend Cometriq as a cost-effective use of NHS resources...